Seelos Therapeutics pauses additional patient enrollment in SLS-005-302 study

Seelos Therapeutics "announced a business update on its key programs. In order to focus the majority of its resources on the ongoing registration directed study of SLS-002 for Acute Suicidal Ideation and Behavior in patients with Major Depressive Disorder and the fully enrolled phase II/III study of SLS-005 in amyotrophic lateral sclerosis, Seelos is temporarily pausing additional enrollment of patients in the SLS-005-302 study in spinocerebellar ataxia type 3. Patients already enrolled will continue in the study and data will continue to be collected in order to make decisions for resuming enrollment in the future. This temporary pause has been implemented as a business decision due to financial considerations, and is not based on any data related to safety or therapeutic effects."